Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals

Abstract

Background Masculinising hormone therapy with testosterone is used to align an individual's physical characteristics with his or her gender identity. Testosterone therapy is typically administered via intramuscular or transdermal routes, and polycythaemia is the most common adverse event. Aims To compare the risk of polycythaemia with different formulations of testosterone therapy in transmasculine individuals. Methods A retrospective cross‐sectional analysis was undertaken of transmasculine individuals at a primary and secondary care clinic in Melbourne, Australia. A total of 180 individuals who were on testosterone therapy for >6 months was included. Groups included those receiving: (i) intramuscular testosterone undecanoate (n = 125); (ii) intramuscular testosterone enantate (n = 31); or (iii) transdermal testosterone (n = 24). Outcome was prevalence of polycythaemia (defined as haematocrit > 0.5). Results Mean age was 28.4 (8.8) years, with a median duration of testosterone therapy of 37.7 (24.2) months; 27% were smokers. There was no difference between groups in serum total testosterone concentration measured. While there was no difference between groups in haematocrit, there was a higher proportion of patients with polycythaemia in those who were on intramuscular testosterone enantate (23.3%) than on transdermal testosterone (0%), P = 0.040. There was no statistically significant difference in polycythaemia between intramuscular testosterone undecanoate (15%) and transdermal testosterone, P = 0.066 nor between intramuscular testosterone enantate and undecanoate, P = 0.275. Conclusions One in four individuals treated with intramuscular testosterone enantate and one in six treated with testosterone undecanoate had polycythaemia. No individual treated with transdermal testosterone had polycythaemia. This highlights the importance of regular monitoring of haematocrit in transmasculine individuals treated with testosterone, and findings may inform treatment choices.

Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals

“…For trans people presumed female at birth who are using masculinizing hormone therapy, testosterone concentrations rise from the female reference range of <2 nmol/L (<0.57 ng/mL) up to the male reference range of 10 to 35 nmol/L (2.88-10.09 ng/mL) ( 7 , 18 , 21 ). It has been noted that despite masculinizing hormone therapy increasing testosterone concentrations, serum estradiol concentrations do not fall dramatically.…”

An introduction to gender-affirming hormone therapy for transgender and gender-nonbinary patients

“…Patients with polycythemia may also be evaluated for other secondary causes, and can consider blood donation or therapeutic phlebotomy for management. Transdermal testosterone may be less likely to induce polycythemia compared with injectable methods 30…”

Approach to the Patient: Pharmacological Management of Trans and Gender-Diverse Adolescents

“…Evaluation and attention to concomitant secondary causes (eg, smoking, obstructive sleep apnea) is important. Data from adult cis ( 61 ) and TGD ( 62 ) cohorts suggest erythrocytosis is highest with short-acting injectable preparations and lower with transdermal preparations. Therapeutic phlebotomy or change of testosterone dose, interval, or preparation may also be considered.…”